Jens Ulrich
Distinguished in Melanoma

Jens Ulrich

Harzklinikum Dorothea Christiane Erxleben GmbH
Quedlinburg, ST, DE 
Distinguished in Melanoma
Harzklinikum Dorothea Christiane Erxleben GmbH
Quedlinburg, ST, DE 
OverviewLocationsClinical Research

Overview

Jens Ulrich practices in Quedlinburg, Germany. Mr. Ulrich is rated as a Distinguished expert by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Giant Congenital Nevus, Metastatic Uveal Melanoma, and Basal Cell Skin Cancer.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 34 articles and participated in 3 clinical trials in the study of Melanoma.

Gender
Male

Locations

Harzklinikum Dorothea Christiane Erxleben GmbH
Quedlinburg, ST, Germany
Other Locations
Elbeklinikum
Buxtehude, NI, Germany
Fachklinik Hornheide
Muenster, NW 48157, Germany
Magdeburg, ST, Germany
Erxleben, ST, Germany
Halle, NI 06099, Germany
Frankfurt Am Main, HE, Germany
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Drug
Study Drug: Vismodegib
Study Phase: Phase 2
An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma
An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Biological
Study Phase: Phase 2
View 3 Less Clinical Trials

72 Total Publications

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ulrich's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile